Boston Scientific Cuts 2026 Organic Revenue Guidance to 6.5–8% After $0.80 EPS Beat
Boston Scientific reported Q1 adjusted EPS of $0.80 while maintaining a 28.0% operating margin, but cut full-year 2026 organic revenue guidance to 6.5%–8.0% from 10%–11%. Greater-than-expected market share loss in its EP Pulsed Field Ablation segment prompted the downgrade and highlights emerging competitive headwinds.
1. Q1 Results and Guidance Revision
Boston Scientific posted Q1 adjusted EPS of $0.80 and sustained a 28.0% operating margin while revising 2026 organic revenue guidance down to 6.5%–8.0% from 10%–11%, signaling slower top-line growth despite profitability control.
2. Competitive Challenges in EP Segment
The Pulsed Field Ablation market saw Boston Scientific’s FARAPULSE system lose more share than expected as Johnson & Johnson’s Varipulse benefits from integration with the CARTO mapping platform, intensifying competition in electrophysiology.
3. Cardiovascular Segment Deceleration
The Cardiovascular segment, which drives roughly 67% of revenue, grew 11.2% organically in Q1 but faces deceleration for the rest of 2026, compounded by underperformance in the WATCHMAN and Urology franchises despite margin discipline.
4. Valuation Reset and Strategic Focus
Shares now trade near 21 times trailing adjusted earnings versus a three-year average of 32x as the narrative shifts from rapid expansion to defending market share against moderating growth headwinds.